NR | CVac | SOC | |
---|---|---|---|
(N = 7) | (N = 29) | (N = 27) | |
Age, years | |||
Mean (SD) | 52.4 (10.3) | 56.8 (8.5) | 56.2 (9.5) |
Median (min, max) | 49 (43–70) | 58 (34–75) | 55 (40-74) |
Race, n (%) | |||
White | 7 (100.0 %) | 26 (89.7 %) | 23 (85.2 %) |
Asian | 0 | 3 (10.3 %) | 2 (7.4 %) |
Black or African American | 0 | 0 | 2 (7.4 %) |
Ethnicity, n (%) | |||
Hispanic or Latino | 0 | 0 | 1 (3.8 %) |
Not Hispanic or Latino | 7 (100.0 %) | 29 (100.0 %) | 25 (96.2 %) |
Cancer stage at enrollment, n (%) | |||
III | 5 (71 %) | 24 (83 %) | 20 (74 %) |
IV | 2 (29 %) | 5 (17 %) | 7 (26 %) |
Histology, n (%) | |||
Serous | 5 (71 %) | 25 (86 %) | 23 (85 %) |
Clear cell | 1 (14 %) | 0 | 0 |
Endometrioid | 0 | 1 (3 %) | 2 (7 %) |
Mixed, serous | 0 | 1 (3 %) | 0 |
Mucinous | 0 | 1 (3 %) | 1 (4 %) |
Other | 1 (14 %)a | 0 | 0 |
Other, mixed | 0 | 1 (3 %)b | 1 (4 %)c |
Cytoreductive Surgery | |||
Optimal | 7 (100 %) | 26 (90 %) | 21 (78 %) |
Sub-optimal | 0 (0 %) | 3 (10 %) | 6 (22 %) |